U.S. market Closed. Opens in 10 hours 31 minutes

HROWM | Harrow Health, Inc. 11.875% Senior Notes due 2027 Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for HROWM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable.

Valuation (5%)

Company Industry
P/E Ratio (TTM) -27.79 -11.39
PEG Ratio (TTM) 6.32 2.22
P/S Ratio (TTM) 12.48 3.14
P/B Ratio (TTM) 15.94 4.50
P/FCF Ratio (TTM) -93.06 -35.66
Price to 5YR AVG Earnings Ratio -63.67 -22.63
Price to 5YR AVG FCF Ratio -549.46 -77.49

Profitability (3%)

Company Industry
ROA (TTM) -10.95% -12.19%
ROE (TTM) -50.73% -18.98%
Net Profit Margin (TTM) -21.78% -13.77%
ROIC 5YR AVG 1.06% 14.83%

Growth (50%)

4QTR AVG 3YR AVG 5YR AVG
EPS -21.60% -861.33% -521.44%
Revenue 11.28% 22.50% 27.34%
Net Income -27.04% -877.82% -537.00%
Cash Flow 145.21% 128.16% 88.65%

Health (51%)

Company Industry
Current Ratio (TTM) 2.60 1.23
Quick Ratio (TTM) 2.43 0.96
D/E Ratio (TTM) 3.17 1.25
Interest Coverage (TTM) -0.75 14.00
Piotroski F-Score 2 5
Altman Z-Score 4.56 2.63
LTL to 5YR AVG FCF -52.31 -5.38
Shares Outstanding Growth 5YR AVG 6.67% 4.60%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙